Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

Overview of attention for article published in Frontiers in Pharmacology, July 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

reddit: 1 Redditor

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 14 Mendeley

Summary X Reddit Dimensions citations

So far, Altmetric has seen 1 X post from an account with 5,779 followers.

New Research: Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer https://t.co/dXztwOX9te #pharmacology

05 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.